CSTL

Castle Biosciences Inc

Add to Watchlist

Advanced Chart

20.090

-0.540(-2.620%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

20.820

Open

20.660

VWAP

20.02

Vol

489.24K

Mkt Cap

579.49M

Low

19.620

Amount

9.80M

EV/EBITDA(TTM)

12.66

Total Shares

27.61M

312.38M

EV/OCF(TTM)

4.82

P/S(TTM)

1.80

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

67.90M

-20.85%

71.82M

-17.45%

80.37M

+10.14%

Estimates Revision

The market is revising Upward the revenue expectations for Castle Biosciences, Inc. (CSTL) for FY2025, with the revenue forecasts being adjusted by 7.33% over the past three months. During the same period, the stock price has changed by -25.76%.

Revenue Estimates for FY2025

Revise Upward

+7.33%

In Past 3 Month

Stock Price

Go Down

-25.76%

In Past 3 Month

7 Analyst Rating

94.13% Upside

Wall Street analysts forecast CSTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 39.00 USD with a low forecast of 30.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

94.13% Upside

Current: 20.090

Low

30.00

Averages

39.00

High

44.00

94.13% Upside

Current: 20.090

Low

30.00

Averages

39.00

High

44.00

Baird

Catherine Ramsey

Buy

Maintains

$36 → $37

2025-02-28

Reason

Baird

Catherine Ramsey

Price Target

$36 → $37

2025-02-28

Maintains

Buy

Reason

Stephens & Co.

Mason Carrico

Buy

Reiterates

$41

2025-01-02

Reason

Stephens & Co.

Mason Carrico

Price Target

$41

2025-01-02

Reiterates

Buy

Reason

Stephens analysts presented the firm's 2025 Best Ideas list, which includes Valley National (VLY), CoStar Group (CSGP), Castle Biosciences (CSTL), Alignment Healthcare (ALHC), Privia Health (PRVA), Vulcan Materials (VMC), South State (SSB), Matson (MATX), Azenta (AZTA), Prog Holdings (PRG), Carvana (CVNA), Blueprint Medicines (BPMC), Truist Financial (TFC), Cognex (CGNX), Fiserv (FI), Hancock Whitney (HWC), SunOpta (STKL), Wingstop (WING), SM Energy (SM), The Andersons (ANDE) and Bank of Marin (BMRC).

Scotiabank

Sung Ji Nam

Buy

Maintains

$37 → $44

2024-11-06

Reason

Scotiabank

Sung Ji Nam

Price Target

$37 → $44

2024-11-06

Maintains

Buy

Reason

Lake Street

Thomas Flaten

Strong Buy

Maintains

$34 → $40

2024-11-05

Reason

Lake Street

Thomas Flaten

Price Target

$34 → $40

2024-11-05

Maintains

Strong Buy

Reason

Lake Street raised the firm's price target on Castle Biosciences to $40 from $34 and keeps a Buy rating on the shares. The firm, which notes that its 2025 revenue estimate is $267.3M, is raising its target after a Q3 beat to reflect better-than-expected testing volumes in several tests and multiple expansion.

Baird

Catherine Ramsey

Buy

Maintains

$37 → $39

2024-11-05

Reason

Baird

Catherine Ramsey

Price Target

$37 → $39

2024-11-05

Maintains

Buy

Reason

Baird analyst Catherine Ramsey Schulte raised the firm's price target on Castle Biosciences to $39 from $37 and keeps an Outperform rating on the shares. The firm said they reported a solid 3Q, with revenue in-line and encouraging OpEx leverage. Overall volumes grew, though dermatology volumes were below estimates due to seasonality, and TissueCypher again demonstrated compelling momentum.

Keybanc

Paul Knight

Buy

Maintains

$28 → $36

2024-11-05

Reason

Keybanc

Paul Knight

Price Target

$28 → $36

2024-11-05

Maintains

Buy

Reason

KeyBanc analyst Paul Knight raised the firm's price target on Castle Biosciences to $36 from $28 and keeps an Overweight rating on the shares. While the determination of coverage for the SCC test will remain a focus, the firm notes the company continues to expand volume for other tests, with growth in IDgenetix and TissueCypher. Strength in these other tests contributed to the strong results for the quarter, as well as the increase in revenue guidance, KeyBanc adds.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Castle Biosciences Inc (CSTL.O) is -12.65, compared to its 5-year average forward P/E of -33.64. For a more detailed relative valuation and DCF analysis to assess Castle Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-33.64

Current PE

-12.65

Overvalued PE

10.93

Undervalued PE

-78.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-27.83

Current EV/EBITDA

-7.66

Overvalued EV/EBITDA

14.86

Undervalued EV/EBITDA

-70.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

7.49

Current PS

2.06

Overvalued PS

13.77

Undervalued PS

1.21

Financials

Annual

Quarterly

FY2024Q4

YoY :

+30.54%

86.31M

Total Revenue

FY2024Q4

YoY :

-171.58%

4.05M

Operating Profit

FY2024Q4

YoY :

-471.71%

9.59M

Net Income after Tax

FY2024Q4

YoY :

-410.00%

0.31

EPS - Diluted

FY2024Q4

YoY :

+13.55%

16.80M

Free Cash Flow

FY2024Q4

YoY :

-2.01%

76.22

Gross Profit Margin - %

FY2024Q4

YoY :

-225.57%

11.00

FCF Margin - %

FY2024Q4

YoY :

-384.87%

11.11

Net Margin - %

FY2024Q4

4.37

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 105.44% over the last month.

Sold

0-3

Months

786.4K

USD

3-6

Months

3.1M

USD

6-9

Months

1.9M

USD

0-12

Months

1.1M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

409.4K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

1.1M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 105.44% over the last month.

Sold

0-3

Months

786.4K

USD

3-6

Months

3.1M

USD

6-9

Months

1.9M

USD

0-12

Months

1.1M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

CSTL News & Events

Events Timeline

2025-04-28 (ET)

2025-04-28

07:10:12

Castle Biosciences test ordered more than 200,000 times

2025-04-03 (ET)

2025-04-03

07:04:48

Castle Biosciences announces publication of papers on DecisionDx-Melanoma test

2025-02-27 (ET)

2025-02-27

16:23:49

Castle Biosciences reports Q4 EPS 32c, consensus 4c

News

9.0

04-25Newsfilter

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

9.5

04-14Newsfilter

Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025

7.5

04-08Newsfilter

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

People Also Watch

CASS

Cass Information Systems Inc

Treace Medical Concepts Inc

Claros Mortgage Trust Inc

2.430

USD

0.00%

FAQ

What is Castle Biosciences Inc (CSTL) stock price today?

The current price of CSTL is 20.09 USD — it has decreased -2.62 % in the last trading day.

CSTL

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

CSTL News & Events

Events Timeline

News

People Also Watch

FAQ

What is Castle Biosciences Inc (CSTL) stock price today?

What is Castle Biosciences Inc (CSTL)'s business?

What is the price predicton of CSTL Stock?

What is Castle Biosciences Inc (CSTL)'s revenue for the last quarter?

What is Castle Biosciences Inc (CSTL)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Castle Biosciences Inc (CSTL)'s fundamentals?

How many employees does Castle Biosciences Inc (CSTL). have?

What is Castle Biosciences Inc (CSTL) market cap?